HomeCompareATBPF vs DGRO

ATBPF vs DGRO: Dividend Comparison 2026

ATBPF yields 927.64% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATBPF wins by $9822464.73M in total portfolio value
10 years
ATBPF
ATBPF
● Live price
927.64%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9822464.76M
Annual income
$8,103,949,924,179.18
Full ATBPF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — ATBPF vs DGRO

📍 ATBPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATBPFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATBPF + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATBPF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATBPF
Annual income on $10K today (after 15% tax)
$78,849.72/yr
After 10yr DRIP, annual income (after tax)
$6,888,357,435,552.30/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, ATBPF beats the other by $6,888,357,435,348.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATBPF + DGRO for your $10,000?

ATBPF: 50%DGRO: 50%
100% DGRO50/50100% ATBPF
Portfolio after 10yr
$4911232.40M
Annual income
$4,051,974,962,209.57/yr
Blended yield
82.50%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATBPF buys
0
DGRO buys
0
No recent congressional trades found for ATBPF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATBPFDGRO
Forward yield927.64%2.13%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$9822464.76M$31.6K
Annual income after 10y$8,103,949,924,179.18$239.96
Total dividends collected$9689719.06M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ATBPF vs DGRO ($10,000, DRIP)

YearATBPF PortfolioATBPF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$103,464$92,764.38$11,293$213.22+$92.2KATBPF
2$1,007,698$896,991.47$12,730$217.32+$995.0KATBPF
3$9,243,012$8,164,775.26$14,326$221.10+$9.23MATBPF
4$79,881,224$69,991,201.10$16,098$224.56+$79.87MATBPF
5$650,788,343$565,315,433.07$18,064$227.74+$650.77MATBPF
6$5,000,639,395$4,304,295,867.45$20,246$230.65+$5000.62MATBPF
7$36,261,047,555$30,910,363,402.53$22,666$233.30+$36261.02MATBPF
8$248,275,740,228$209,476,419,343.92$25,349$235.73+$248275.71MATBPF
9$1,606,088,634,392$1,340,433,592,348.06$28,325$237.94+$1606088.61MATBPF
10$9,822,464,762,978$8,103,949,924,179.18$31,624$239.96+$9822464.73MATBPF

ATBPF vs DGRO: Complete Analysis 2026

ATBPFStock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Full ATBPF Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this ATBPF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATBPF vs SCHDATBPF vs JEPIATBPF vs OATBPF vs KOATBPF vs MAINATBPF vs VIGATBPF vs NOBLATBPF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.